Rigel Pharmaceuticals, Inc. Aktie News

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS SOUTH SAN FRANCISCO, Calif. , Oct. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in the dose expansion ph...

SOUTH SAN FRANCISCO, Calif. , Oct. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDA...

Rigel Pharmaceuticals is a commercial-stage biotech growing revenue with three marketed drugs and a promising pipeline. RIGL's product sales grew 72% YoY in 1H FY2025, with diversification reducing reliance on TAVALISSE and GAVRETO showing strong adoption. On FY2025 revenue projections, Rigel trades at ~2.8x forward EV/sales; valuing the company in line with the sector median implies a share pr...

SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in Se...

Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, expecting positive net income and robust sales growth, signaling Rigel's transition to a self-sustaining, growth-focused biotech. Pipeline progress, especially with R289 and REZLIDHIA label expansio...

Rigel (RIGL) Q2 Revenue Jumps 176%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants David A. Santos - Executive VP & Chief Commercial Officer Dean L.

Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million  Completed enrollment in the dose escalation part of the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in patients with R/R lower-risk MDS Generated $59.6 million of net income in the second quarter of...